Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 10 records per page: next > | last >>
pages: 1 2 3 4 5 ... 7 8 9 10 presentations: 1 to 25 of 248
New targets on the KRAS pathway
Frank McCormick
UCSF Helen Diller Family Comp. Cancer Ctr., San Francisco, CA, United States
from AACR Annual Meeting 2014 on April 5, 2014 1:00 PM-3:00 PM
Chairperson
Lucy A Godley
Univ. of Chicago, Chicago, IL, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Histone profiling by ChIP-sequencing and mass spectrometry: methods and applications
Kathrin Maria Bernt
The Center for Cancer and Blood Disorders, Denver, CO, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Methods to distinguish 5-methylcytosine from 5-hydroxymethylcytosine
Lucy A Godley
Univ. of Chicago, Chicago, IL, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Next-generation sequencing-based methods for the study of cytosine modifications in primary leukemia specimens
Maria Eugenia Figueroa
U. of Michigan, Ann Arbor, MI, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Computational analysis of whole genome bisulfite sequencing data
Wei Li
Baylor College of Medicine Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Introduction
Mario Sznol
Yale Cancer Ctr., New Haven, CT, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Targeting checkpoint receptors: Beyond CTLA-4 and PD-1
Ana C. Anderson
Harvard Medical School/Brigham & Women's Hospital, Boston, MA, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Targeting the B7-H family and BTLA inhibitory receptors for cancer treatment
Drew M. Pardoll
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Harnessing the power of TNF-receptor family members to enhance immune-mediated rejection of tumors
Andrew D Weinberg
Robert W. Franz Cancer Research Center, Portland, OR, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Oncogenic alterations of metabolism
Chi Van Dang
Abramson Cancer Ctr. of Univ. of Penn., Philadelphia, PA, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
How cancer powers biosynthesis and redox defense
Joshua D Rabinowitz
Princeton Univ., Princeton, NJ, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Role of altered metabolism in cancer
Matthew G. Vander Heiden
MIT Koch Inst. for Integrated Cancer Res., Cambridge, MA, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Stable isotope-resolved metabolomic (SIRM) approach: From bench to bedside
Teresa W. m. Fan
University of Kentucky, Lexington, KY, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Introduction to Workshop
Lee M. Ellis
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Advancing through the phases of clinical trials (What is a phase I-III clinical trial, and what purposes do they serve)
S. Gail Eckhardt
Univ. of Colorado Cancer Ctr., Aurora, CO, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
How are clinical trials funded
Neal J. Meropol
University Hospitals Seidman Cancer Center & Case Western Reserve University, Cleveland, OH, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
What role does the FDA play in cancer clinical trials
Elizabeth M. Jaffee
Johns Hopkins Univ., Baltimore, MD, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Standard and functional imaging and its role in determining endpoints in clinical trials (including modified RECIST criteria for biologics)
Richard L. Wahl
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
CDK4/6 inhibition: Cellular outcomes, synthetic lethal interactions with oncogene activation and clinical development of selective compounds
Geoffrey I. Shapiro
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Cyclin E-amplified ovarian cancer: Tumor biology and treatment strategies
David D L Bowtell
Peter MacCallum Cancer Ctr., E. Melbourne, Australia
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Drugging the cell cycle checkpoint regulator Chk1
Alan Eastman
Norris Cotton Cancer Ctr., Lebanon, NH, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Cdc20 as a novel therapeutic target for cancer treatment
Wenyi Wei
Beth Israel Deaconess Medical Ctr., Boston, MA, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Cancer evolution at single-cell genomic resolution
Nicholas E. Navin
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
Experimental and mathematical approaches to dissect breast tumor evolution
Kornelia Polyak
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2014 on April 5, 2014 8:00 AM-10:00 AM
<< first | < prev page: of 10 records per page: next > | last >>
pages: 1 2 3 4 5 ... 7 8 9 10 presentations: 1 to 25 of 248